Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Authors
Keywords
-
Journal
Current Obesity Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-03
DOI
10.1007/s13679-022-00474-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
- (2021) Chloe Wong et al. Frontiers in Endocrinology
- Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
- (2021) Masato Yoneda et al. BMJ Open Diabetes Research & Care
- Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
- (2021) Caiyun Zheng et al. Cardiovascular Diabetology
- Clinical Adverse Events Associated with Sodium–Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals
- (2021) Donna Shu-Han Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
- (2021) Stergios A. Polyzos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
- (2021) Abdul M. Majzoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
- (2021) Evangelia S. Makri et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial Effects of Glucagon-Like Peptide 1 Receptor Agonists on Glucose Control, Cardiovascular Risk Profile, and Non-Alcoholic Fatty Liver Disease. An Expert Opinion of the Italian Diabetes Society
- (2021) Raffaele Napoli et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Pharmacotherapy of obesity: An update
- (2021) Andrea Cignarella et al. PHARMACOLOGICAL RESEARCH
- Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
- (2021) Yi-Zhou Huang et al. World Journal of Diabetes
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cilofexor for the treatment of nonalcoholic steatohepatitis
- (2021) Stergios A. Polyzos et al. Current Vascular Pharmacology
- Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
- (2021) Nick Finer DIABETES OBESITY & METABOLISM
- Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
- (2021) Cheng Han Ng et al. Endocrine Practice
- Nonalcoholic fatty liver disease: lifestyle and quality of life
- (2021) Ilias Vachliotis et al. Hormones-International Journal of Endocrinology and Metabolism
- A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
- (2021) Samit Ghosal et al. Scientific Reports
- A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men
- (2021) Naoko Nakanishi et al. Scientific Reports
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
- (2020) Francisca dos Santos Coelho et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
- (2020) Jai Kumar et al. DIGESTIVE AND LIVER DISEASE
- Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
- (2020) Evangelia Makri et al. ARCHIVES OF MEDICAL RESEARCH
- Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials
- (2020) Harpreet S. Bajaj et al. DIABETES OBESITY & METABOLISM
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial
- (2019) Dario Tuccinardi et al. DIABETES OBESITY & METABOLISM
- Epidemiology of chronic liver diseases in the USA in the past three decades
- (2019) Zobair M Younossi et al. GUT
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
- (2019) Vasiliki Venetsanaki et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?
- (2018) Stergios A. Polyzos et al. HEPATOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
- (2018) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes
- (2018) H.S. Bajaj et al. DIABETES & METABOLISM
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
- (2018) Simona Leoni et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- (2018) Francesco Bifari et al. PHARMACOLOGICAL RESEARCH
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups
- (2017) Shiv Chitturi et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
- (2016) William N. Hannah et al. Clinics in Liver Disease
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) et al. DIABETOLOGIA
- Emerging and future therapies for nonalcoholic steatohepatitis in adults
- (2016) Gesthimani Mintziori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Nonalcoholic fatty future disease
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review
- (2016) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies
- (2016) L. Li et al. Obesity Reviews
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2015) Laura J Carbone et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Nonalcoholic Fatty Liver Disease
- (2012) Stergios A. Polyzos et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: An Endocrine Society Clinical Practice Guideline
- (2010) David Heber et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
- Orlistat-Associated Adverse Effects and Drug Interactions
- (2009) Theodosios D Filippatos et al. DRUG SAFETY
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
- (2009) Prospective Studies Collaboration LANCET
- Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
- (2008) Stephen A. Harrison et al. HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now